Want to dig deeper on Olympus Corp and thousands of companies?
Rapidly search an extensive universe of public and private content — earnings transcripts, company filings, equity research, trade journals, and more.
Request a Free TrialCompanies by industry
Aerospace & DefenseAutomobile ComponentsAutomobilesBanksBeveragesBiotechnologyBroadline RetailCapital MarketsChemicalsCommunications EquipmentConsumer FinanceConsumer Staples Distribution & RetailContainers & PackagingElectric UtilitiesElectronic Equipment, Instruments & ComponentsEnergy Equipment & ServicesEntertainmentFinancial ServicesFood ProductsGround TransportationHealth Care Equipment & SuppliesHealth Care Providers & ServicesHotels, Restaurants & LeisureHousehold DurablesHousehold ProductsIT ServicesIndustrial ConglomeratesIndustrial REITsInsuranceInteractive Media & ServicesLife Sciences Tools & ServicesMachineryMediaMetals & MiningMulti-UtilitiesOil, Gas & Consumable FuelsPersonal Care ProductsPharmaceuticalsSemiconductors & Semiconductor EquipmentSoftwareSpecialized REITsSpecialty RetailTechnology Hardware, Storage & PeripheralsTextiles, Apparel & Luxury GoodsTobaccoWireless Telecommunication Services
Olympus Corp Earnings - Analysis & Highlights for Q3 2025
Overview
PositivesNegativesOutlook
- Consolidated revenue increased by 9% YoY to ¥725.2 billion with yen depreciation serving as a tailwind.
- Medical services saw a steady growth across all regions, especially in Europe and North America, due to stable revenue streams based on service contracts, including maintenance services and an increase in new accounts.
- The company is confident that the initiatives through project Elevate will continue to have positive effects for the future clearance and approvals and submissions and will lead to sustainable growth.
- The company is making progress on the FDA submission for the EDOF scopes and its plans for local manufacturing in China.
- The company is excited and positive about the reorganization from a technology out to a marketing type of approach, not only internally but also with customers.
- Sales and product mix, cost of goods are worsening.
- Sales revenue in China is declining and that is having an impact.
- Sales declined in China due to the impact of the anti-corruption campaign and others.
- Sales in Surgical Endoscopy declined in China.
- The company is struggling with the availability of the corresponding latest generation endoscopes.
- The company expects Japan, Europe, and APAC sales growth to be flat, not as much as China.
- The company expects a 15% to 20% decline in sales for the full year.
- The company expects sales and product mix, and cost of goods to worsen.
- The company expects to reduce its cost base from September and October.
Q&A Highlights from Olympus Corp Earnings Call Q3 2025
- Analyst asked about the target for the remainder of the medium-term management plan and whether the company can further improve its operating margin through lean operations.
- Yasuo Takeuchi, President and CEO of Olympus, explained that the company's policy remains unchanged, and they are trying to strengthen their fundamental strength to become a true global MedTech company. He also mentioned that the company is currently in the final phase of putting together a new business plan for the next fiscal year, but cannot disclose specific details.
- Yasuo Takeuchi, President and CEO of Olympus, explained that the company's policy remains unchanged, and they are trying to strengthen their fundamental strength to become a true global MedTech company. He also mentioned that the company is currently in the final phase of putting together a new business plan for the next fiscal year, but cannot disclose specific details.
- Analyst asked about the reason behind the profit decline in Q3, specifically in China.
- The profit decline in Q3 was primarily due to weakness in China, specifically in the ESD segment, which has the highest profitability. Additionally, the company had lower sales in key markets such as the UK, South Korea, and Australia, compared to the previous year.
- The profit decline in Q3 was primarily due to weakness in China, specifically in the ESD segment, which has the highest profitability. Additionally, the company had lower sales in key markets such as the UK, South Korea, and Australia, compared to the previous year.
- Analyst asked about the factors behind the ¥24 billion downward revision.
- The downward revision is mainly due to ESD-related factors, with China being the biggest factor. The company had expected sales to decline slightly, but a 15% to 20% decline is now being observed. Additionally, product mix and cost of goods are worsening, and the company had originally expected sales growth in Japan, Europe, and APAC, but now expects the numbers to be flat.
- The downward revision is mainly due to ESD-related factors, with China being the biggest factor. The company had expected sales to decline slightly, but a 15% to 20% decline is now being observed. Additionally, product mix and cost of goods are worsening, and the company had originally expected sales growth in Japan, Europe, and APAC, but now expects the numbers to be flat.
- Analyst asked about the factors contributing to the downward revision in sales and regional factors, R&D, and impairment.
- The speaker confirmed that these are the only factors contributing to the downward revision.
- The speaker confirmed that these are the only factors contributing to the downward revision.
- Analyst asked about the impact of VBP and whether it is the main factor contributing to the downward revision.
- The speaker explained that the impact of VBP is the biggest factor contributing to the downward revision, specifically for the EndoTherapy business. The speaker mentioned that VBP is advancing faster than expected.
- The speaker explained that the impact of VBP is the biggest factor contributing to the downward revision, specifically for the EndoTherapy business. The speaker mentioned that VBP is advancing faster than expected.
- Analyst asked about the timing of the ESD and TSD launches.
- The company plans to launch ESD first, followed by TSD, but they are considering the possibility of a simultaneous launch.
- The company plans to launch ESD first, followed by TSD, but they are considering the possibility of a simultaneous launch.
- Analyst asked about the reasons for the downward revision of guidance.
- The company revised its guidance downward due to a continued sluggish performance in the UK, Korea, and Russia, as well as the failure of China to recover as expected. The company had anticipated a recovery in China and a return to normalcy in other markets, but these factors did not materialize.
- The company revised its guidance downward due to a continued sluggish performance in the UK, Korea, and Russia, as well as the failure of China to recover as expected. The company had anticipated a recovery in China and a return to normalcy in other markets, but these factors did not materialize.
- Analyst asked about the company's plans for increasing its budget for medical infrastructure in the UK for the next fiscal year.
- The company expects to increase its budget for medical infrastructure in the UK for the next fiscal year.
- The company expects to increase its budget for medical infrastructure in the UK for the next fiscal year.
- Analyst asked about the company's plans for implementing organizational changes, specifically regarding products and how they will be managed.
- The company has separated its organizations into two main categories: surgical intervention and GI EndoTherapy. The surgical intervention category includes capital products such as scopes, while GI EndoTherapy focuses on GI-focused specialties. The company will be taking care of different organ surgeries under the SIS division, while GIS will handle GI-focused specialties.
- The company has separated its organizations into two main categories: surgical intervention and GI EndoTherapy. The surgical intervention category includes capital products such as scopes, while GI EndoTherapy focuses on GI-focused specialties. The company will be taking care of different organ surgeries under the SIS division, while GIS will handle GI-focused specialties.
Related Companies:
